Bevacizumab. Metastatic colorectal cancer: Good in theory, not in practice

Prescrire International

Volumn 15, Issue 83, 2006, Pages 94-97

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; CETUXIMAB; CYTOTOXIC AGENT; FLUOROURACIL; FOLINIC ACID; IBRITUMOMAB TIUXETAN; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; RADIOISOTOPE; RITUXIMAB; TRASTUZUMAB; VASCULOTROPIN ANTIBODY; YTTRIUM 90; CAMPTOTHECIN; DRUG DERIVATIVE;

ANGIOGENESIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ARTERY THROMBOSIS; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MARKETING; EPISTAXIS; EUROPE; EVIDENCE BASED MEDICINE; FREQUENCY ANALYSIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART INFARCTION; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; INFECTION; INTERSTITIAL PNEUMONIA; INTESTINE PERFORATION; LEUKOPENIA; METASTASIS; NEPHROTIC SYNDROME; PROGNOSIS; PROTEINURIA; RECTUM HEMORRHAGE; RESPIRATORY TRACT DISEASE; RISK BENEFIT ANALYSIS; SKIN TOXICITY; STATISTICAL SIGNIFICANCE; STOMATITIS; STROKE; SURVIVAL TIME; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TUMOR BLEEDING; VEIN THROMBOSIS; WOUND HEALING IMPAIRMENT; COLORECTAL TUMOR; COMPARATIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CAMPTOTHECIN; CLINICAL TRIALS; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; NEOPLASM METASTASIS; SURVIVAL; TREATMENT OUTCOME;

EID: 33744795448     PISSN: 11677422     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Prescrire Editorial Staff "Chemotherapy of metastatic colorectal cancer" Prescrire Int 2005; 14 (80): 230-233.
2. European Medicines Agency - CHMP "European Public Assessment Report Avastin Scientific discussion": 61 pages; placed online on the EMEA website on 28 January 2005.
3. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Application number STN-125085/0 - Medical review" 26 February 2004: 217 pages.
4. U.S. Food and Drug Administration - Center for Drug Evaluation and Research "Application number STN-125085/0 - Statistical review" 20 February 2004: 47 pages.
5. Hurwitz H et al. "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer" N Engl J Med 2004; 350 (23): 2335-2342 + 351 (16): 1690-1691.
6. Prescrire Editorial Staff "Irinotecan" Prescrire Int 2001; 10 (52): 41-43.
7. Kabbinavar FF et al. "Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FV/LV alone in patients with metastatic colorectal cancer" J Clin Oncol 2003; 21: 60-65.
8. Kabbinavar FF et al. "Addition of bevacizumab in first-line metastatic colorectal cancer to bolus fluorouracil and leucovorin: results of a randomized phase II trial" J Clin Oncol 2005; 23: 3697-3705.
9. Kabbinavar FF et al. "Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer" J Clin Oncol 2005; 23: 3706-3712.
10. Reddy GK "The addition of bevacizumab to FOLFOX 4 prolongs survival in relapsed colorectal cancer: interim data from ECOG 3200 trial" Clin Colorectal Cancer 2005: 4 (5): 300-301.
11. Genentech "Genentech provides update on phase II study with Avastin in platinum-refractory ovarian cancer" 23 September 2005: 2 pages.
12. o (bevacizumab)" January 2005: 28 pages.